Pharmafile Logo

Cell and gene therapy manufacturing

- PMLiVE

Novartis buys gene therapy firm AveXis for $8.7bn

Lead candidate AVXS-101 could potentially replace regular drug treatment for SMA with a one-off intervention

Celgene building

Celgene boosts CAR-T stake again with Bluebird Bio deal

The US biotech could receive $70m in development milestones for the candidate

- PMLiVE

GSK buys Novartis out of consumer health JV after ditching Pfizer bid

Will pay $13bn for the 36.5% stake owned by the Swiss drug maker

- PMLiVE

Can value-based healthcare take off and reach for the skies?

Are companies willing to contribute to the change in the healthcare system?

- PMLiVE

Novartis pushes ‘virtual’ clinical trial concept

Teams up with Science 37 to run ten digital-based trials over the next three years

Novartis telemedicine service to be ramped up in Ghana

Country's health service selects it as part of the national eHealth strategy

- PMLiVE

FDA hands GSK a reprieve by blocking Novartis generic

The Advair rival could be delayed until 2019

Novartis day

Novartis doubles down on biosimilars with Biocon alliance

The companies will develop multiple immunology and oncology biosimilars

- PMLiVE

Novartis gets speedy reviews for new Kymriah filings

US and EU regulatory agencies will review the drug for DLBCL patients

- PMLiVE

Novartis joins biosimilar Humira push in US

Pharma giant hopes its candidate will follow in the footsteps of Amgen’s Amjevita and BI’s Cyltezo

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links